Categories: News

Spago Nanomedical Presents its Q1 Report and Provides Company Update

LUND, SE / ACCESSWIRE / April 20, 2022 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)

Spago Nanomedical AB (publ) publishes its interim report for January-March 2022 on Tuesday, 27 April, 2022 at 08.00 CEST. On the same day, at 13.00 CEST, the company management presents the report and also provides an update on the company’s operations. The presentation will be held in English.

The presentation will be held at Penser Bank AB, Apelbergsgatan 27, Stockholm, and can be followed digitally, live and afterwards via the following link: https://youtu.be/pqfdg9mqf0E.

Registration for participation at Penser Bank is made to http://enews.penser.se/public/event/RegistrationForm/43435C427041465A4B7840.

For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se

Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.

FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, info@fnca.se.

Attachments

Spago Nanomedical presents its Q1 report and provides company update

SOURCE: Spago Nanomedical

View source version on accesswire.com:
https://www.accesswire.com/698132/Spago-Nanomedical-Presents-its-Q1-Report-and-Provides-Company-Update

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

2 hours ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

2 hours ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

5 hours ago